Drug safety outsourcing varies among similar sized firms

By Nick Taylor

- Last updated on GMT

Related tags: Outsourcing, Employment

More than 50 per cent of large pharma keep all pharmacovigilance in-house but among smaller firms, and even some big businesses, outsourcing is considerable, according to a new report.

Outsourcing pharmacovigilance can help companies manage workloads, tap expertise and remove the need to add in-house capacity. Despite these benefits, 56 per cent of large pharma companies polled by Cutting Edge Information (CEI) ​keep all pharmacovigilance in-house.

In a report​ CEI explains that large pharma companies’ strong technology infrastructure and ability to attract qualified, experienced employees limit their outsourcing. Also, these firms’ portfolios, pipelines and resources make keeping pharmacovigilance in-house practical and feasible.

However, even among large pharma companies outsourcing can account for a significant proportion of pharmacovigilance budget. The report cites a large pharma company which outsources 50 per cent of its pharmacovigilance activities.

Also, a pharma company, which outsources 15 per cent of pharmacovigilance, explains that it uses vendors for risk evaluation and mitigation strategies (REMS). The firm reasons that it is uneconomical to employ a full-time REMS specialist who will only be needed a few times a year.

Every small company polled outsources some of their pharmacovigilance work but the amount varies from 10 per cent up to 80 per cent. Consequently, although in general smaller firms outsource more, there is no consistent standard even among similar sized companies.

Vendor offerings

The poll also looks at companies preferences for outsourcing to vendors who provide turnkey or ad hoc ​services. Of the large companies polled, 50 per cent choose to outsource each activity separately.

These businesses already have a pharmacovigilance infrastructure in place and use vendors to deal with spikes in demand. This removes the need to hire and fire in-house employees.

In contrast, small and medium sized firms prefer outsourcing partners that can provide turnkey and ad hoc ​services. The report believes that the flexibility offered by these vendors is attractive to pharmacovigilance departments facing constantly changing workloads and resources.

Related news

Related products

show more

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 17-Jan-2022 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Planning Your Preclinical Assessment

Planning Your Preclinical Assessment

Altasciences | 17-Jan-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Related suppliers

Follow us


View more